The clinical analysis of milrinone in the treatment of chronic pulmonary heart disease

Objective To investigate the clinical effect of milrinone in the treatment of chronic pulmonary heart disease. Method 134 patients with chronic pulmonary heart disease were randomly divided into observation group and control group, 32 case in each group. Control group patients were treated with conventional therapy, observation group patients were treated with milrinone based on control group, the effective rate, pulmonary function, blood gas index and adverse reaction were contrasted between the two groups. Result The effective rate of observation group was higher than control group(P 0.01). There were no significant differences in FVC, forced expiratory volume(FEV1), pulmonary arterial pressure(PAP), Pa CO2 and Pa O2 between the two groups before treatment(P 0.05). After treatment, FEV1, Pa O2, FVC were significantly higher than before treatment(P 0.05), and observation group was significantly higher than control group(P 0.01), Pa CO2 and PAP were significantly lower than before treatment, observation group was significantly lower than control group(P 0.01). There were no significant difference in adverse reaction rate between the two groups(χ2= 0.2078, P = 0.6485). Conclusion Milrinone can effectively reduce the pulmonary hypertension in patients with pulmonary heart disease, improve lung function and heart function, improve blood oxygen saturation, has curative effects, worthy of clinical application.